Article

Antiapoptotic mechanism of cannabinoid receptor 2 agonist on cisplatin-induced apoptosis in the HEI-OC1 auditory cell line.

Department of Pharmacology, College of Oriental Medicine, Kyung Hee University, Seoul, Republic of Korea.
Journal of Neuroscience Research (impact factor: 2.74). 04/2007; 85(4):896-905. DOI:10.1002/jnr.21168
Source: PubMed

ABSTRACT Cisplatin is a highly effective chemotherapeutic agent but with significant ototoxic side effects. Apoptosis is an important mechanism of cochlear hair cell loss following exposure to an ototoxic level of cisplatin. The present study investigated the effects of the cannabinoid receptor 2 (CB2) ligand JWH-015 on cisplatin-induced apoptosis. CB2 mRNA was constitutively expressed in the auditory cell line HEI-OC1. By using MTT assay, DNA fragmentation, and FACS analysis, we demonstrated that apoptosis induced by cisplatin was inhibited by treatment with JWH-015 in a dose-dependent manner. Activation of caspase-3, caspase-8, and caspase-9 was detected after treatment with cisplatin, and the cleavage of poly-(ADP)-ribose polymerase (PARP) was observed within cisplatin-treated HEI-OC1 cells. JWH-015 inhibited the activation of caspase-3, caspase-8, and caspase-9; cleavage of PARP; and release of cytochrome c. JWH-015 also inhibited the apoptosis through activation of the extracellular signal-regulated kinase pathway. Finally, JWH-015 inhibited cisplatin-induced reactive oxygen species and tumor necrosis factor-alpha production. Collectively, these findings show that blocking a critical step in apoptosis by using JWH-015 may be a useful strategy to prevent harmful side effects of cisplatin ototoxicity in patients having to undergo chemotherapy.

0 0
 · 
0 Bookmarks
 · 
34 Views
  • Source
    Article: Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction.
    [show abstract] [hide abstract]
    ABSTRACT: Cannabinoids have been proposed to possess neuroprotective properties; though their mechanism of action remains contentious, they are posited to prevent neurodegenerative disorders, including Parkinson's disease, the pathogenesis of which has not been established. Recent studies have demonstrated that induction of proteasomal dysfunction in animal models results in a phenotype similar to Parkinson's disease. Here, we investigated the neuroprotective function of a synthetic cannabinoid-receptor agonist (WIN55.212.2) in dopaminergic neuronal death induced by a proteasomal synthase inhibitor (PSI), additionally testing the hypothesis that WIN55.212.2 modulates cytoplasmic accumulation of parkin and α-synuclein, a key feature of proteasomal dysfunction in Parkinson's. WIN55.212.2 protects PC12 cells from PSI-induced cytotoxicity, concomitantly inhibiting PSI-induced polyADP ribose polymerase expression and activation of caspase-3. While PSI induces cytoplasmic accumulation of α-synuclein and parkin, WIN55.212.2 counters these effects. Interestingly, however, while PSI induces the activation and nuclear translocalization of nuclear factor κB, WIN55.212.2 potentiates this effect. These data are suggestive that WIN55.212.2 might confer a neuroprotective benefit in PSI-induced proteasomal dysfunction, and could further protect against neuronal degeneration stemming from cytoplasmic accumulation of α-synuclein and parkin. These results indicate that WIN55.212.2 may be a candidate for treatment of neurodegenerative diseases, including Parkinson's disease.
    Anatomy & cell biology 06/2011; 44(2):135-42.

Keywords

Activation
 
auditory cell line HEI-OC1
 
cannabinoid receptor 2
 
chemotherapy
 
Cisplatin
 
cisplatin ototoxicity
 
cisplatin-induced apoptosis
 
cisplatin-treated HEI-OC1 cells
 
cochlear hair cell loss
 
DNA fragmentation
 
dose-dependent manner
 
effective chemotherapeutic agent
 
extracellular signal-regulated kinase pathway
 
FACS analysis
 
harmful side effects
 
JWH-015 inhibited cisplatin-induced reactive oxygen species
 
MTT assay
 
poly-(ADP)-ribose polymerase
 
significant ototoxic side effects
 
tumor necrosis factor-alpha production